Pfizer drops phase 2 diabetes drug, two earlier-stage candidates

Pfizer has quietly dropped three drug candidates from its pipeline.

During its financials posted today, Pfizer quietly updated its pipeline showing that it has dropped three candidates from its testing programs, but as always, details were thin on the ground.

Its most advanced prospective med from this list was its Type 2 diabetes drug PF-06291874, a glucagon receptor antagonist that finished a midstage test last year.

According to, Pfizer was testing the drug in over 200 patients against placebo in a three-month study in Type 2 diabetics who couldn’t control their sugar levels using metformin. The study was completed in fall of last year, but data were not made available on the site.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Pfizer also ditched two phase 1 studies for PF-06815345, a small molecule that was aimed at hyperlipidemia, and PF-06412562, for an unspecified cognitive disorder, within its pain and neuroscience division.

Again, looking to, Pfizer had been testing the latter compound in schizophrenia, with the study being completed in October of last year. 


Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.